Similar articles

• It is likely that the risk of cardiovascular events from pharmaceuticals as COX-2 inhibitors can be reduced significantly by standard pharmaceutical and lifestyle preventative measures.

  Hellstrom HR. Hellstrom HR. Med Hypotheses. 2006;67(6):1333-7. doi: 10.1016/j.mehy.2006.05.027. Epub 2006 Jun 30. Med Hypotheses. 2006. PMID: 16814480
• What price pain relief?

  Hochman JS, Shah NR. Hochman JS, et al. Circulation. 2006 Jun 27;113(25):2868-70. doi: 10.1161/CIRCULATIONAHA.106.634386. Epub 2006 Jun 19. Circulation. 2006. PMID: 16785335 No abstract available.
• Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.

  American Gastroenterological Association; Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, Grosser T, Hunt R, Ladabaum U, Lanas A, Paulus H, Regueiro C, Sandler RS, Simon L. American Gastroenterological Association, et al. Clin Gastroenterol Hepatol. 2006 Sep;4(9):1082-9. doi: 10.1016/j.cgh.2006.04.010. Epub 2006 Jul 31. Clin Gastroenterol Hepatol. 2006. PMID: 16877048 No abstract available.
• Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.

  Vardeny O, Solomon SD. Vardeny O, et al. Cardiol Clin. 2008 Nov;26(4):589-601. doi: 10.1016/j.ccl.2008.06.004. Cardiol Clin. 2008. PMID: 18929233
• [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].

  Lange H, Eberhart L. Lange H, et al. Anasthesiol Intensivmed Notfallmed Schmerzther. 2007 Jul;42(7):514-7. doi: 10.1055/s-2007-985503. Anasthesiol Intensivmed Notfallmed Schmerzther. 2007. PMID: 17661262 Review. German.